

Supplemental Material

WARCEF Committees and Investigators

Executive Committee

S. Homma, J.L.P Thompson, P. Pullicino, R. Freudenberger, S. Graham, J. Teerlink, S. Ammon, D. Mann, J.P. Mohr, R.L. Sacco, B. Massie, S. Anker, A. Labovitz, and C. Moy

National Institute of Neurological Disorders and Stroke

C. Moy, P. Gilbert, L. Gutmann, and J. Marler; Clinical Coordinating Center: S. Homma, V. Mejia, A. Gabriel, S. Borden, E. Peña, C. Harris, R. Khadouri, D. Gohs, M. Brown, G. Berry, D. Disantis, M. Scullin, P. Smith, S. Kohsaka, W. Watson, and L. Guillory; Statistical Coordinating Center: J. L. P. Thompson, B. Levin, R. Buchsbaum, M. Del Valle, A. Sanford, G. Levy, K. Tea, J. Grier, L. Swydan, B. O'Hare, R. Proadhan, R. Arbing, E. Flanagan, E. Duverger, A. Peljto, W. Lo, A. Tierney, A. Henriquez, and J. Keen; Data and Safety Monitoring Board: G.J. del Zoppo, G.W. Albers, M. Eliasziw, J.A. Hinchey, K.C. Johnston, A.M. Lowe, I.L. Piña and J.A. Swain;

Endpoint Adjudication Committee

J.R. Teerlink, S. Ammon, S. Slomiak, and L. Cape; Neurology Adjudicators: H.J.M. Barnett, A. Bruno, J.D. Easton, S. Levine, and D. Sahlas; Cardiology Adjudicators: F. Bleyer, P. Carson, A. Ellis, A. Miller, and S.T. Palmeri;

Core Echo Lab

A. Labovitz, M. Di Tullio, M. Bierig, R. Liu, and C. Donato; Hemorrhage adjudicator: R. Hart.

Clinical Research Organizations

Clinsys (United States and Canada): C. McKay, L. Wilson, E. Frey, K. Hayward, P. Stein-Beal and L. Konczarek; Charite (Germany, Poland and Netherlands): M. Diek, M. Rohwedder, M. Bohdanowicz-Zazula, C.F. Peerenboom-Fey and M. Vissienon; Verum (Hungary and Ukraine): G. Rex, M. Varga, O. Kovtun and V. Orlyk; FGK (Czech Republic and Slovakia): P. Arenberger and J. Jaros. STAT Research (Argentina): A. Ruiz, M. Zimmermann and A. Ellenberg.

Complete list of WARCEF Sites

The following institutions, investigators, and coordinators enrolled patients in the trial (shown in parenthesis is the number of patients randomized at the site): **United States**, LSU Health Sciences Center (66): A. Minagar, R. Kelley, J. McGee, P. Jenkins, and S. Bezucha; Buffalo General Hospital (53): S. Graham, V. Hart, M. Bonora, R. Sawyer, and K. Ammerman; Detroit VA Medical Center (50): P. Ramappa, V. Berchou, E. Jones, and E. Olgren; Denver VA Medical Center (38): B. Hattler, C. Anderson, B. Watson, and D. Wolf; UMDNJ - New Brunswick (29): J. Kosits, S. Palmeri, and L. Casazza; Mayo Clinic – Transplant Center (28): D. Yip, J. Meschia, A. McPhail, and K. Greenan; LeBauer Cardiovascular Research (28): R. Rothbart, J. Love, T. Schrader, and V. Garman; Louisville VA Medical Center (27): M. Stoddard, K. Rimmel, and R. Longaker; UMDNJ - Newark (26): C. Gerula, M. Klapholz, J. Kirmani, and R. Mattessich; Columbia University Medical Center (24): M. Di Tullio, C. Rodriguez, and A. Gabriel; Reno VA Medical Center (22): W. Graettinger, A. Baker, and A. Valencia; Madison VA Medical Center (22): P. Kosolcharoen, and L. Williams; University of Arizona Health Sciences Center (21): V. Sorrell, B. Coull, and D. Bruck; Morehouse School of Medicine (20): E. Ofili, M. Frankel, and P. Jackson; Cardiac Care and Vascular Medicine, PLLC (20): M. Nanna, J. Yasen, S. Sparr, and W. Almeida; Long Island Jewish Medical Center (20): R. Libman, B. Stephens, and C. DeMers; Gulf Regional Research, LLC (20): T. Giles, L. Roffidal, and D. Barratt; Veterans Affairs Medical Center (19): M. Liston, C. Lindsey, and L. Giron; Virginia Commonwealth University (18): W. Felton III, L. Joseph, and M. Lee; University of Rochester Medical Center (16): J. Bisognano, C.

Benesch, and L. Caufield; Santa Clara Medical Center (16): E. Nishime, M. Moussavian, and E. Polland; Black Hills Health Care System (16): L. Fischer, K. Peterson, and B. McGinnis; Lahey Clinic (15): M. Tilem, G. Allam, and J. Beebe; University of North Carolina at Chapel Hill (14): P. Chang, S. Sen, and C. Schuler; L.J. Chabert Medical Center (14): L. Arcement, M. Charlet, and E. Falgout; Sewickley Valley Medical Group, Cardiology (14): M. Malkowski, T. Dugan, and J. Hobbs-Williams; West Los Angeles VA Medical Center (14): A. Warner, K. Panizzon, and J. Johnson; Albert Einstein Medical Center (13): J. Dissin, D. Karia, and N. Molakala; Melbourne Internal Medicine Associates (11): B. Dandapani, R. Vicari, and E. Anthony; The Cleveland Clinic Foundation (11): I. Katzan, R. Hobbs, and A. Richmond; Denver Health Medical Center (11): R. Hughes, W. Baker, and M Applegate; Penn Presbyterian Medical Center (11): B. Drachman, S. Khella, and S. Donovan; Brooke Army Medical Center MCHE - MDC Cardiology Service (10): A. Slim, and D. Pearce Moore; Mount Sinai Medical Center (10): B. Darrow, and A. Travis; The Westchester Medical Group (10): A. Mercado, and R. Pellegrino; Salem VA Medical Center (10): N. Jarmukli, and T. Ochalek; St. Louis University Hospital (9): D. Janosik, and J. Dizes; University of Kentucky (9): L.C. Pettigrew, and D. Taylor; MetroHealth Medical Center (7): J. Hanna, and S. Bailey; Hackensack University Medical Center (7): R. Berkowitz, and S. Mathus; Huntington VA Medical Center (6) V. Virkud, and S. Shaw; Lehigh Valley Hospital (6): R. Freudenberger, and S. Nabhan; Winthrop University Hospital (5): E. Wirkowski, and B. George; Central Arkansas VA Medical Center (5): E. Smith, and S. Locke; Connecticut Heart and Vascular Center, PC (5): C. Landau, and D. Ferguson; University of Texas Medical School - Houston (5): H.V. Anderson, and L. Westbrook; Cincinnati VA Medical Center (5): M. Apelian, and S. Khoury; Berkshire Medical Center (5): J. Leppo, and T. Bator; Richmond VA Medical Center (4): W. Felton III, and M. Lee; University of Louisville (4): M. Stoddard, and R. Longaker; Oklahoma City VA Medical Center (4): U. Thadani, and J. Turner; Southern Arizona VA Health Care System (4): S. Goldman, and S. Daugherty; Methodist Heart, Lung and Vascular Institute (4): A. Adler, and T. Rennie; Tri-State Medical Group Cardiology (4): M. Malkowski, and D. Chupka; George Washington University (4): R. Katz, and L. Witkin; Rochester General Hospital (3): W. S. Burgin, and C. Weber; Penn State Milton S. Hershey Medical Center (3): J. Boehmer, and P. Frey; Kaleida Health Millard Fillmore Hospital (3): M. Wilson, and H. Tworek; Northport VA Medical Center (3): G. Mallis, and D. Mauceri; Holy Cross Medical Group (3): R. Schneider, and W. Schneider; Jackson Memorial Hospital (3): G. Ortiz, and M. Lichtenberger; Northeast Georgia Heart Center (3): B. Hott, and D. Patrick; Rush University Medical Center (2): S. Dunlap, and S.J. Kim; Fallon Clinic, Inc. (2): S. Pezzella, and D. Aubin; Temple University Hospital (2): L. Nikolaidis, and J. Wong; North Shore University Hospital (1): D. Leifer, and M. Rossi; Methodist Hospital - Physician Association (1): G. Torre, and J. Arredondo; Mayo Clinic Scottsdale (1): J. Lynch, and A. Metcalf; Watson Clinic Center for Research, Inc. (1): J. Gonzalez, and B. Donley; Hospital of the University of Pennsylvania (1): T. Cappola, and K. Craig; Houston VA Medical Center (1): B. Bozkurt, and M. Bolos; Blackstone Cardiology Associates (1): T. Noonan, and C. Alteri; **Poland**, Wroclaw Military Hospital (68): P. Ponikowski, L. Kowalczyk, A. Cwynar, D. Drazek, and J. Biegus; Specjalistyczny Szpital im dr A. Sokoloskiego (41): R. Szelemej, M. Jurczok, R. Serafin, and A. Jurczyk; Samodzielny Szpital Wojewodzki (33): M. Ogorek, D. Kopcik, B. Metzkier-Wyrwa, and A. Szczepanska; The Medical University of Warsaw (22): M. Dluzniewski, M. Modzelewski, W. Wicha, and M. Kuch; SP ZOZ Szpital Wojewodzki (22): K. Kuc, R. Piotrowski, and O. Lesniak; Spzoz Szpital Miejski Nr 2 (15): M. Krauze-Wielicka, J. Herman, and S. Nowakowska; Miedzyleski Szpital Specjalistyczny (15): T. Pasierski, B. Kozlowski, and K. Wolkowska; NZOZ Poradnia Kardiologiczna Centrum-Serce (11): A. Juszcak, J. Michalska, and I. Jedlinski; SCBK Pro Cordis (8): P. Miekus, and M. Konarzewski; SP ZOZ Klodzko (8): P. Berkowski, and N. Jacek; Slaskie Centrum Chorob Serca (8): Z. Kalarus, and A. Duszanska; Szpital Zespolony (5): J. Tarchalski, and P. Czaja; Medical University of Warsaw (5): Z. Gaciong, and J. Gora; SP Szpital Wojewodzki im. Papieza Jana Pawla II (2): A. Kleinrok, and G. Prokop-Lewicka; **Canada**, Ottawa Heart Institute (41): H. Haddad, R. Davies, L. Sitwell, and J. Donaldson; Etobicoke Cardiac Research Centre (29): T. To, R. Yufe, and B. Donnelly; Montreal General Hospital (21): T. Huynh, R. Cote, and B. St. Jacques; Brampton Research Associates (20): D. Borts, G. Tullio, and A.M. Sindilar; Center for Neurologic Research (19): T. Winder, E. Janzen and C. Walker; St. Michael's

Hospital (19): G. Moe, N. Bayer, and A. Konig; London Health Sciences Centre (14): M. Arnold, D. Spence, and J. Smith; Saint John Regional Hospital (13): R. Bessoudo, P. Bailey, and A. McNulty; Sudbury Cardiac Research (10): S. Nawaz, and C. Dewar; QE II Health Sciences Centre (10): M. Rajda, and M. MacFarlane; Jewish General Hospital (6): J. Minuk, and C. Schanz; Vancouver Island Health Research Center (6): A. Penn, and L. Atkins; Montreal Heart Institute (4): A. Ducharme, and H. Brown; St. Boniface General Hospital (4): S. Zieroth, and A. Muñoz; **Netherlands**, Deventer Ziekenhuis Cardiologie Research (73): D. Lok, J.B.M. ten Holter, C. Huls, P. Bruggink-Andre, and A. van Buijisen-Nutters; Jeroen Bosch Ziekenhuis (39): M. Daniels, A. Coppes, M.van Zagten, and N. Elzebroek; Tweesteden Ziekenhuis (22): K. Hamroui, P. L. M. de Kort, and J. Vuijsters; Elisabeth Ziekenhuis (16): N. Holwerda, W. Hermans, and R. van der Loo; Medisch Spectrum Twente (14): E. Wajon, G. Hageman, and G. v. Buchem-Damming; Reiner de Graaf Gasthuis (11): E. Ronner, A. Wissenburg-van Lieshout, and H. Niekus; Groene Hart Ziekenhuis (9): M.W.J. van Hessen, and G.A.M. Verheul; Twenteborg Ziekenhuis (2): G. Linssen, and L. te Pas; Ziekenhuis Hilversum (2): J. Plomp, and P.A.R. de Milliano; Medisch Centrum Leeuwarden (1): R. Breedveld, and M.J. Bos; **Czech Republic**, Kolin Hospital, Internal Dept. (44): M. Houra, D. Beran, and R. Lebedova; Trebic Kardiologicka Ambulance (20): J. Carda, E. Bednarova, and J. Vosmerova; Slany Municipal Hospital (17): G. Marcinek, T. Drasnar, and O. Najmanova; Litomysl Hospital, Internal Dept. (15): M. Dunaj, E. Pechackova, and M. Kuchar; Motol Faculty Hospital (14): P. Jansky, J. Simon, and H. Dvorakova; Prague Cardiological Clinic (13): P. Gregor, M. Maruskova, and L. Svoboda; Cardiology Outpatient Clinic Pilsen (13): Z. Lorenc, and P. Kralicek; Soukroma Kardiologicka ambulance Opava (9): L. Pollak, Z. and M. Krobot; Brno Faculty Hospital, Internal and Cardiological Dept. (6): J. Spinar, and M. Nemecek; St. Ann's Hospital Brno, (5): L. Spinarova, and R. Kuba; Prague Faculty Hospital Na Bulovce (3): F. Padour, and I. Padourova; Prague Homolka Hospital (3): M. Padour, and M. Michalova; The Charles University Hospital (3): L. Golan, and M. Hajkova; CARDIOMED s.r.o. (3): J. Povolny, and L. Krizova; Liberec District Hospital (2): D. Horak, and P. Kucera; IKEM Cardiological Clinic (2): I. Malek, and B. Krizova; Health Centre of Cardiology, Trutnov (1): J. Svoboda, and R. Ferkl; **Hungary**, Karolyi Hospital (44): L. Regos, L. Csuros, O. Lovasz, and G. Kiss; Bacs-Kiskun County Hospital (31): S. Timar, N. Torok, and A. Hajnalne; Uzsoki Hospital (30): B. Palossy, A. Nagy, P. Fulop, and G. Jakab; Peterfy Hospital (13): A. Ronaszeki, M. Bodi, and M. Satori; Medical and Health Science Center, Debrecen (5): I. Edes, and I. Varga; Dr. Bugyi Istvan Hospital (5): A. Kovacs, and L. Berente; DRC Gyógyszervizsgáló Központ Kft. (5): E. Péterfai, and R. Pauer; Ferenc Jahn Hospital (4): K. Toth, and E. Nagy; Hetenyi Hospital (4): B. Benczur, and K. Karsay; Erzsebet County Hospital (3): T. Végh, and R. Nagy; St. Stephan Hospital (3): P. Karpati, and Z. Davidovits; National Institute of Cardiology (2): J. Borbola, and J. Vanyi; Toldy Ferenc Hospital (2): B. Oze and A. Bujdoso; Veszprem megyei Csolnoky Ferenc Kórház-Rendelőintézet (1): I. Kosa, and L. Baliko; **Germany**, Medical Practice Dr. Natour (46): M. Natour, M. Morgil, E. Hartmann, and H. Morgil; Ludwigshafen Clinic (18): R. Winkler, S. Gass, and S. Baumann; Medical Practice Dr. Jeserich (18): M. Jeserich, J. Rodl, and M. Dzaiy; Charité Berlin (16): S. Anker, G. Turhan, and K. Wolf; Johannes Gutenberg University (10): S. Genth-Zotz, and T. Siebert; Medical Practice Dr. Jakobs (9): C. Jakobs, and M. Kiorwantsi; Georg August University (7): B. Pieske, and R. Wachter; Leipzig Medical Network (4): M. Schoenauer, and S. Voigt; Schleswig-Holstein University Hospital (4): H. Schunkert, and A. Boguschewski; Regensburg University Hospital (1): M. Resch, and R. Wensel; Gesellschaft fur Innovative Therapie (1): V. Schumann and P. Heidrich; **Ukraine**, National Medical University (27): O. Girina, Y. Prokopovych, M. Lebedynska, and I. Sorokina; City Clinical Hospital #1, Kiev (21): O. Karpenko, N. Brodi, and S. Klochkov; M.D. Stazhesko Institute of Cardiology (17): L. Voronkov, Y. Besaga, and O. Novikova; Kyiv Central Clinical Hospital (12): K. Amosova, O. Yaremenko, and K. Balaban; M.D. Strazhesko Institute of Cardiology of AMS (9): V. Kovalenko, and N. Polenova; Department Therapy of Stomatology faculty of National Medical University (9): I. Sakharchuk, and A. Ogorodnichuk; Kiev City Clinical Hosp of Ambulance (8): L. Rudenko, and Y. Tutov; M.D. Strazhesko Institute of Cardiology of AMS (6): A. Parkhomenko, and S. Kozhukhov; Odessa Municipal Clinical Hospital #9 (4): E. Yakimenko, and S. Kolomiets; Odessa State Medical University (2): V. Yurlov, and S. Tikhonova; **Argentina**, Centro Neurologico de Tratamiento y Rehabilitacion (25): C. Estol, A. Elizalde,

and B. Mangariello; CIPREC (12): C. Zaidman, and F. Guerlloy; Hospital Fernandez (11): P. Gitelman, K. Crotto, and S. Sassone; Grupo Medico Alem (11): J. Aiub, and F. Novoa; CICLO/Instituto de Cardiologia La Plata (10): R. Lopez Santi, and P. Romia; CEDIMBA (Ramos Mejia) (8): O. Montaña, and D. Malchik; Instituto Medico Adroque (Centro Adroque) (6): F. Sokn, and P. Schygiel; UAI Hospital Universitario (5): R. Porcile, and F. Soria Tito; Instituto Cardiovascular de Buenos Aires (2): J. Thierer, and P. Avellana; Sanatorio Itoiz, Avellaneda (2): C. Rapallo, and M. Calderon; **United Kingdom**, City Hospital, Birmingham (41): R. MacFadyen, R. Haynes, and J. Partridge; **Slovakia**, III. Interna klinika, FNŠP Nemocnica ak. L. Dévera (11): M. Kokles, S. Mehešová, and A. Zachar; KARDIOCENTRUM NITRA s.r.o. (11): M. Hranai, T. Varadyova, and T. Göbö; Kardiocentrum TN sro (5): J. Litvinova, and P. Loviska.

Table S1. Selection Procedure Model Results

	DF	Parameter Estimate	Standard error	X²	p-value	HR
Treatment=warfarin (among those under 60)	1	-0.456	0.143	10.187	0.001	0.634
Treatment=warfarin (among those 60 or older)	1	0.540	0.182	8.785	0.003	1.087
Gender=female	1	-0.519	0.127	16.682	<0.001	0.595
BUN (mg/dL - centered at mean)	1	0.017	0.004	15.289	<0.001	1.017
Ejection Fraction (% - centered at mean)	1	-0.024	0.006	13.896	<0.001	0.976
Six Minute Walk distance (m - centered at mean)	1	-0.001	0.000	11.715	0.001	0.999
Diabetes Mellitus	1	0.323	0.098	10.804	0.001	1.381
Hemoglobin (g/dL - centered at mean)	1	-0.103	0.033	9.484	0.002	0.902
Peripheral Vascular Disease	1	0.348	0.124	7.923	0.005	1.417
Diastolic BP (mmHg - centered at mean)	1	-0.010	0.004	5.505	0.02	0.990
BMI > 30	1	-0.200	0.110	3.324	0.07	0.818
BMI < 25	1	0.191	0.108	3.124	0.08	1.210
Age 60 years or older (among ASA patients)	1	0.137	0.131	1.092	0.30	1.146
Age 60 years or older (among WAR patients)	1	0.677	0.142	22.804	<0.001	1.968

Table S2A. Demographics and Baseline Characteristics for Patients under 60 years old.

	Warfarin (N=508)	Aspirin (N=522)
Age – yr	50 +/- 7.3	51 +/- 7.2
Male sex – %	406 (80.2%)	415 (79.8%)
Race – % *		
White, non-Hispanic	359 (70.9%)	367 (70.7%)
Black, non-Hispanic	99 (19.6%)	109 (21%)
Hispanic	33 (6.5%)	28 (5.4%)
Other	15 (3%)	15 (2.9%)
Height – cm	173 +/- 9.1	173 +/- 9.2
Weight – kg	91 +/- 21.6	91 +/- 21.9
BMI†	30 +/- 6.8	30 +/- 7
< 25	122 (24.3%)	113 (22%)
25-30	151 (30.1%)	177 (34.5%)
> 30	229 (45.6%)	223 (43.5%)
Blood pressure – mmHg		
Systolic	122 +/- 19.5	122 +/- 18.3
Diastolic	77 +/- 11.9	76 +/- 11.7
Pulse - bpm	75 +/- 11.7	74 +/- 13.1
Hypertension – %	283 (58.4%)	301 (58.8%)
Diabetes Mellitus – %	135 (26.7%)	128 (24.7%)
Atrial Fibrillation – %	10 (2%)	18 (3.5%)
Myocardial Infarction – %	187 (37%)	207 (40%)
Ischemic Cardiomyopathy – %	172 (34.1%)	185 (35.8%)

Smoking Status – %		
Current	134 (26.5%)	121 (23.3%)
Past	225 (44.6%)	246 (47.4%)
Never	146 (28.9%)	152 (29.3%)
Alcohol consumption (>2 oz./day) – %		
Current	116 (22.9%)	132 (25.4%)
Past	122 (24.1%)	133 (25.6%)
Never	268 (53%)	254 (48.9%)
Education – %		
Less than High School	183 (36.2%)	201 (38.9%)
HS Grad/ Some College	256 (50.6%)	223 (43.1%)
College Grad/Post Grad	67 (13.2%)	93 (18%)
NYHA Classification – % [‡]		
I	71 (14.1%)	65 (12.6%)
II	271 (53.8%)	293 (56.8%)
III	158 (31.3%)	148 (28.7%)
IV	4 (0.8%)	10 (1.9%)
Ejection Fraction (%)	24 +/- 7.1	24 +/- 7.4
6-Minute Walk (m) [§]	363 +/- 135.4	360 +/- 149.3
Prior Stroke or TIA – %	66 (13.1%)	56 (10.8%)
Modified Rankin Scale		
(all patients) – %		
0	206 (41%)	223 (43.1%)
1	162 (32.2%)	153 (29.5%)
2	119 (23.7%)	123 (23.7%)
3	14 (2.8%)	18 (3.5%)
4	2 (0.4%)	1 (0.2%)

Modified Rankin Scale^{ll}

(prior stroke/TIA) – %

0	16 (24.6%)	15 (26.8%)
1	24 (36.9%)	20 (35.7%)
2	22 (33.8%)	17 (30.4%)
3	2 (3.1%)	4 (7.1%)
4	1 (1.5%)	0 (0.0%)

Medication Use – %[¶]

Aspirin** ^{††}	247 (54.5%)	280 (59.6%)
Other antiplatelet**	8 (4.8%)	14 (8.4%)
Warfarin or other OAC ^{††}	38 (7.5%)	41 (7.9%)
ACE Inhibitor or ARB	499 (99.2%)	515 (99.2%)
Beta blocker	466 (92.6%)	477 (91.9%)
Aldosterone blocker**	196 (67.8%)	190 (67.4%)
Nitrate	104 (20.7%)	117 (22.5%)
Calcium channel blocker	44 (8.7%)	35 (6.7%)
Diuretic	419 (83.3%)	425 (81.9%)
Statin**	273 (80.5%)	291 (82.9%)

Device Use – %

Pacemaker	51 (10.1%)	54 (10.4%)
Defibrillator	99 (19.6%)	100 (19.3%)

Plus-minus values are means \pm SD. The difference between Warfarin and Aspirin in education was statistically significant at the alpha=0.05 level (p=0.027). Continuous variables were compared with Student's t-test. Binary categorical variables were compared using Fisher's Exact Test, and multi-category variables were compared using standard chi-squared tests.

* Race and ethnicity were self-reported separately, and were combined for presentation.

[†] Body-mass index (BMI) is weight in kilograms divided by the square of height in meters.

‡ The NYHA Classification groups HF patients according to extent of limitation during physical activity. Class I indicates no limitation; Class IV indicates severe limitation.

§ Six minute walk distances were available for 458/508 patients in the warfarin group and 478/522 patients in the aspirin group.

|| Scores on the modified Rankin scale ranged from 0 to 4 on a scale of 0 to 6, with 0 indicating no symptoms and 6 indicating death. A score > 4 was a protocol exclusion.

¶ From the screening visit case report form.

** Not asked of all patients.

†† Prior to randomization.

Table S2B. Demographics and Baseline Characteristics for patients at least 60 years old.

Characteristic	Warfarin (N=634)	Aspirin (N=641)
Age – yr	69 +/- 6.7	69 +/- 6.3
Male sex – %	498 (78.5%)	521 (81.4%)
Race – %*		
White, non-Hispanic	498 (78.5%)	509 (79.5%)
Black, non-Hispanic	67 (10.6%)	57 (8.9%)
Hispanic	52 (8.2%)	53 (8.3%)
Other	17 (2.7%)	21 (3.3%)
Height – cm	170 +/- 9.3	171 +/- 9.1
Weight – kg	82 +/- 16.8	83 +/- 16.2
BMI [†]	28 +/- 4.9	28 +/- 4.9
< 25	172 (27.2%)	152 (23.9%)
25-30	275 (43.4%)	279 (43.9%)
> 30	186 (29.4%)	205 (32.2%)
Blood pressure – mmHg		
Systolic	125 +/- 19	126 +/- 18.2
Diastolic	72 +/- 10.9	73 +/- 10.7
Pulse - bpm	70 +/- 10.7	70 +/- 11.6
Hypertension – %	388 (62.7%)	395 (64.1%)
Diabetes Mellitus – %	236 (37.3%)	223 (35%)
Atrial Fibrillation – %	34 (5.4%)	24 (3.8%)
Myocardial Infarction – %	362 (57.3%)	356 (55.8%)
Ischemic Cardiomyopathy – %	316 (49.9%)	318 (49.8%)

Smoking Status – %		
Current	79 (12.5%)	74 (11.6%)
Past	356 (56.2%)	353 (55.2%)
Never	198 (31.3%)	212 (33.2%)
Alcohol consumption (>2 oz./day) – %		
Current	163 (25.7%)	161 (25.2%)
Past	128 (20.2%)	123 (19.2%)
Never	343 (54.1%)	355 (55.6%)
Education – %		
Less than High School	307 (48.4%)	301 (47.2%)
HS Grad/ Some College	231 (36.4%)	237 (37.1%)
College Grad/Post Grad	96 (15.1%)	100 (15.7%)
NYHA Classification – % [‡]		
I	79 (12.5%)	100 (15.7%)
II	350 (55.3%)	353 (55.4%)
III	193 (30.5%)	181 (28.4%)
IV	11 (1.7%)	3 (0.5%)
Ejection Fraction (%)	25 +/- 7.8	26 +/- 7.6
6-Minute Walk (m) [§]	332 +/- 154.9	353 +/- 155.1
Prior Stroke or TIA – %	89 (14.1%)	83 (13%)
Modified Rankin Scale		
(all patients) – %		
0	257 (40.8%)	266 (41.6%)
1	191 (30.3%)	206 (32.2%)
2	143 (22.7%)	143 (22.4%)
3	32 (5.1%)	22 (3.4%)
4	7 (1.1%)	2 (0.3%)

Modified Rankin Scale^{||}

(prior stroke/TIA) – %

0	24 (27%)	23 (27.7%)
1	26 (29.2%)	23 (27.7%)
2	26 (29.2%)	31 (37.3%)
3	10 (11.2%)	5 (6%)
4	3 (3.4%)	1 (1.2%)

Medication Use – %[¶]

Aspirin** ^{††}	364 (61.3%)	352 (58.6%)
Other antiplatelet**	24 (9.2%)	26 (8.8%)
Warfarin or other OAC ^{††}	52 (8.2%)	48 (7.5%)
ACE Inhibitor or ARB	619 (97.8%)	624 (97.8%)
Beta blocker	560 (88.5%)	559 (87.5%)
Aldosterone blocker**	210 (55.7%)	217 (54.7%)
Nitrate	180 (28.4%)	142 (22.2%)
Calcium channel blocker	56 (8.9%)	68 (10.7%)
Diuretic	506 (79.9%)	505 (79%)
Statin**	417 (85.5%)	413 (82.6%)

Device Use – %

Pacemaker	90 (14.2%)	90 (14.1%)
Defibrillator	113 (17.9%)	106 (16.6%)

Plus-minus values are means \pm SD. Continuous variables were compared with Student's t-test. Binary categorical variables were compared using Fisher's Exact Test, and multi-category variables were compared using standard chi-squared tests. The differences between warfarin and aspirin were significant at the alpha=0.05 level for six minute walk distance (p=0.020) and nitrate use (p=0.012).

* Race and ethnicity were self-reported separately, and were combined for presentation.

† Body-mass index (BMI) is weight in kilograms divided by the square of height in meters.

‡ The NYHA Classification groups HF patients according to extent of limitation during physical activity. Class I indicates no limitation; Class IV indicates severe limitation.

§ Six minute walk distances were available for 573/634 patients in the warfarin arm and 593/641 patients in the aspirin arm.

|| Scores on the modified Rankin scale ranged from 0 to 4 on a scale of 0 to 6, with 0 indicating no symptoms and 6 indicating death. A score > 4 was a protocol exclusion.

¶ From the screening visit case report form.

** Not asked of all patients.

†† Prior to randomization.